knowledge -WSS

knowledge

author：comprehensive 2025-09-28 23:48:19 - browse：34

Axovant Sciences(AXON) is the main event in biotech’s September cavalcade of clinical trial readouts, but while we wait, it’s a good idea to prep for important — and stock-moving — data releases from Zogenix(ZGNX) and Amicus Therapeutics(FOLD).

Zogenix’s lead drug, called ZX008, is a low-dose liquid formulation of the old serotonin booster fenfluramine. The company is developing ZX008 to treat children with Dravet syndrome, a rare and severe type of epilepsy.

You might remember fenfluramine as part of the “fen-phen” obesity regimen that was pulled from the market in 1997 because fenfluramine (at a higher dose) caused severe damage to people’s heart valves.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Dobbs anniversary: the lost opportunity of abortion as health care
Next article： Why we need to separate burnout from moral injury in health care

entertainment

knowledge

WSS

BioMarin wins approval for gene therapy to treat hemophilia A

New guidelines on severe brain injury complicate already difficult decisions

What does generative AI mean for health care? We asked experts

Heart attack and stroke risk calculators need revising

Guidelines to prevent youth baseball injuries need more muscle

Ask STAT: What do you want to know about ChatGPT in medicine?

Wikipedia

knowledge

hotspot

United colonoscopy coverage change 'may cost lives,' doctors say

Medicare proposal to cover medical devices draws a mixed reaction

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Malaria cases in Florida and Texas: Here’s what you need to know

How one medical school became remarkably diverse

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Why we need to separate burnout from moral injury in health care

FDA approval of Sarepta Duchenne genetic therapy gives me hope

In age of alternative facts, a scholarly course on calling out crap

hotspot

Medical records are filled with copy

What would happen to your eyes if you looked at the solar eclipse?

With FDA staff opposed to Sarepta therapy, top official intervened

In Memoriam: Notable people who died in 2023

Drug repurposing or repositioning? The language matters

Trump demands the U.S. pay no more for drugs than other countries … again

Wikipedia

entertainment

knowledge

hotspot